CryoPort (NASDAQ:CYRX) is gearing up to announce its quarterly earnings on Tuesday, 2026-03-03. Here's a quick overview of what investors should know before the release.

Analysts are estimating that CryoPort will report an earnings per share (EPS) of $-0.20.

CryoPort bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Overview of Past Earnings

In the previous earnings release, the company beat EPS by $0.03, leading to a 7.48% drop in the share price the following trading session.

Here's a look at CryoPort's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.21	-0.21	-0.27	-0.31
EPS Actual	-0.18	-0.24	-0.28	-0.42
Price Change %	-7.48	29.82	23.32	30.63

Stock Performance

Shares of CryoPort were trading at $8.42 as of February 27. Over the last 52-week period, shares are up 62.45%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Discovering CryoPort: A Closer Look

CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.

CryoPort: A Financial Overview

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: CryoPort's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 15.44%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -20.22%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): CryoPort's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.88%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): CryoPort's ROA stands out, surpassing industry averages. With an impressive ROA of -1.16%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: CryoPort's debt-to-equity ratio is below the industry average. With a ratio of 0.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

To track all earnings releases for CryoPort visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.